Antidepressant drug discovery in the postgenomic era

World Journal of Biological Psychiatry

Volumn 2, Issue 4, 2001, Pages 165-177

  Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

antidepressant drug discovery; depression; functional phenotyping; genotyping; proteomics

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE; SUBSTANCE P;

DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; GENOTYPE; HUMAN; MAJOR DEPRESSION; METABOLISM; REVIEW; SMOOTH MUSCLE; STANDARD;

ADRENOCORTICOTROPIC HORMONE; ANTIDEPRESSIVE AGENTS; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION; GENOTYPE; HUMANS; MUSCLE, SMOOTH; NEUROPEPTIDES; SUBSTANCE P;

EID: 0035497640     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970109026805     Document Type: Review

References (44)

1. Carney RM, Freedland KE, Rich MW, Jaffe AS (1995) Depression as a risk factor for cardiac events: a review of possible mechanisms. Ann Behav Med 17:142-149.
2. Chakravarti A (1999) Population genetics - making sense out of sequence. Nat Genet 21:56-60.
3. Chawla MK, Gutierrez, GM, Young WS, McMullen NT, Rance NE (1997) Localization of neurons expressing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol 384:429-442.
4. Eisenberg D, Marcotte EM, Xenarios I, Yeates TO (2000) Protein function in the post-genomic era. Nature 405:823-826.
5. Flattem NL, Blakely RD (2000) Modified structure of the human serotonin transporter promoter. Mol Psychiatry 5:110-115.
6. Frasure-Smith N, Lesperance F, Talajic M (1993) Depression following myocardial infarction: impact on 6-month survival. JAMA 270:1819-1825.
7. Glassman AH, Shapiro PA (1998) Depression and the course of coronary artery disease. Am J Psychiatry 155:4-11.
8. Hasenöhrl RU, Jentjens O, De Souza S, Tomaz C, Huston JP (1998) Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region. Eur J Pharmacol 354:123-133.
9. Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33:181-214.
10. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
11. International Human Genome Sequencing Consortium (2001) Inititial sequencing and analysis of the human genome. Nature 409:860-921.
12. 1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:171-380.
13. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek IJ, Reines SA, Snavely D, Wyatt-Knowles E, Hale EJ, et al (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
14. Lancel M, Wigger A, Landgraf R, Müller-Preuss P, Holsboer F (In Press) The CRHR-R1 antagonist R121919 attenuates stress-eliceted sleep disturbances in rats, particularly in those with high innate anxiety. J Psychiatr Res.
15. Lesch KP, Heils A (2000) Serotonergic gene transcriptional control regions: targets for antidepressant drug development? Int J Neuropsychopharmacol 3:67-79.
16. Lundberg JM, Hökfelt T (1983) Coexistence of peptides and classical neurotransmitters. Trends Neurosci 6:325-333.
17. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE, Wan JS, Jackson MR, Erlander MG (1999) Gene expression profiles of laser-captured adjacent neuronal subtypes. Nature 5:117-122.
18. McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, Siok CJ, Lowe JA, Heym J (1991) Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 251:437-439.
19. Musselman DJ, Evans DL, Nemeroff CB (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55:580-592.
20. Nomura H, Shiosaka S, Tohyama M (1987) Distribution of substance P-like immunoreactive structures in the brain stem of the adult human brain: an immunocytochemical study. Brain Res 404:365-370.
21. Nussdorfer GG, Malendowicz LK (1998) Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 19:949-968.
22. Penninx BWJH, Beekman ATF, Honig A, Deeg DJH, Schoevers RA, van Eijk JTM, van Tilburg W (2001) Depression and cardiac mortality. Arch Gen Psychiatry 58:221-227.
23. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirschner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
24. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001) Linkage disequilibrium in the human genome. Nature 411:199-204.
25. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405:857-865.
26. 1) antagonists. TIPS 20:485-490.
27. Schwarze SR, Hruska KA, Dowdy SF (2000) Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 10:290-295.
28. Serretti A, Lilli R, Lorenzi C, Casperini M, Smeraldi E (1999) Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 33:371-377.
29. Serretti A, Lorenzi C, Lilli R, Smeraldi E (2000) Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 34:89-98.
30. Shen LX, Basilion JP, Stanton Jr VP (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci 96:7871-7876.
31. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
32. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior. J Neurosci 14:2579-2584.
33. Stout SC, Owens MJ, Nemeroff CB (1999) Preprotachykinin-A and neurokinin 1 receptor mRNA expression are unchanged in rat forebrain after chronic antidepressant administration. Soc Neurosci Abstracts 25:1066.
34. Taillon-Miller P, Gu Z, Li Q, Hillier L, Kwok PY (1998) Overlapping genomic sequences: a treasure trove of single-nucleotide polymorphisms. Genome Res 8:748-754.
35. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
36. The International SNP Map Working Group (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933.
37. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JMHM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Mice lacking a functional corticotropin-releasing hormone receptor 1 show impaired stress response and reduced anxiety under basal and alcohol withdrawal conditions. Nat Genet 19:162-166.
38. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000) Penetration of amitriptyline, but not fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1 a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387.
39. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and ß-endorphin. Science 213:1394-1397.
40. Venter JC, Adams MC, Myers EW, Li PW, Mural J, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al (2001) The sequence of the human genome. Science 291:1304-1350.
41. Wittchen HU (2000) Depression 2000. Eine bundesweite Depressions- Screening-Studie in Allgemeinarztpraxen. Fortschr Med Suppl, Sonderheft 1/2000.
42. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.
43. Zill P, Baghai TC, Zwanzger P, Schüle C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B (2000) Evidence for an association between a G-protein ß3-gene variant with depression and response to antidepressant treatment. NeuroReport 11:1893-1897.
44. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.